MILAN, Italy—The first choice of therapy for patients with metastatic kidney cancer who have failed VEGF therapy has changed according to experts at the 2016 European Multidisciplinary Meeting on Urological Cancers (EMUC) who assessed phase 3 study data on two different agents—each of which showed clinically meaningful improvements to outcomes.
“There is a new treatment algorithm for individuals who have failed VEGF-targeted therapy,” said Thomas Powles, MBBS MRCP MD, Director of Barts Cancer Centre at St Bartholemews Hospital in London, UK.
“Both the ESMO and EAU guidelines are [now] supporting nivolumab and cabozantinib rather than—[as] previously—supporting axitinib and everolimus.”
He based his comments on observations from the METEOR and CheckMate 025 studies which found that therapy with cabozantinib or nivolumab improved overall survival compared to everolimus.
Peter Goodwin discusses the details of the METEOR findings with him.